このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Pediatrix Medical Group マネジメント

マネジメント基準チェック /24

Pediatrix Medical Group'sの CEO はJim Swiftで、 Jan2023年に任命され、の在任期間は 1.58年です。の年間総報酬は$ 2.24Mで、 29%給与と71%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.21%を直接所有しており、その価値は€ 1.75M 。経営陣と取締役会の平均在任期間はそれぞれ2.6年と4.1年です。

主要情報

Jim Swift

最高経営責任者

US$2.2m

報酬総額

CEO給与比率	29.0%
CEO在任期間	1.7yrs
CEOの所有権	0.2%
経営陣の平均在職期間	2.7yrs
取締役会の平均在任期間	4.2yrs

経営陣の近況

Recent updates

CEO報酬分析

Pediatrix Medical Group の収益と比較して、Jim Swift の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	n/a	n/a	-US$252m
Mar 31 2024	n/a	n/a	-US$71m
Dec 31 2023	US$2m	US$650k	-US$60m
Sep 30 2023	n/a	n/a	US$88m
Jun 30 2023	n/a	n/a	US$95m
Mar 31 2023	n/a	n/a	US$98m
Dec 31 2022	US$1m	US$450k	US$63m

報酬と市場: Jimの総報酬 ($USD 2.24M ) は、 German市場 ($USD 1.46M ) の同規模の企業の平均を上回っています。

報酬と収益: Jimの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Jim Swift (62 yo)

1.7yrs

在職期間

US$2,237,839

報酬

Dr. James D. Swift, M.D., also known as Jim, is Director of Brave Care, Inc. since October 2021. He had been the Chief Operating Officer at Pediatrix Medical Group, Inc. since May 2022 until December 31, 2...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
James Swift	CEO & Director	1.7yrs	US$2.24m	0.20% $ 1.7m
C. Richards	Executive VP & CFO	4yrs	US$1.78m	0.21% $ 1.8m
Mary Ann Moore	Executive VP	1.9yrs	US$1.83m	0.19% $ 1.6m
John Pepia	Senior VP & Chief Accounting Officer	8.3yrs	US$1.43m	データなし
Cheryl VanPatten	Senior VP & Chief Information Officer	2.7yrs	データなし	データなし
Daniel Corcoran	Senior Vice President of Administration & Managed Care	no data	データなし	データなし
Charles Lynch	Senior VP of Finance	no data	データなし	データなし
Meghan Lublin	Senior VP	3.1yrs	データなし	データなし
Mike Ashford	President of Regional Operations (Central)	no data	データなし	データなし
Michael Dwyer	President of Regional Operations (South-Central)	no data	データなし	データなし
Nanette Sanders	Senior Vice President of Operations	no data	データなし	データなし
Linda Chen	President of Regional Operations (West)	2.4yrs	データなし	データなし

2.7yrs

平均在職期間

61.5yo

平均年齢

経験豊富な経営陣: PDCの経営陣は経験豊富であると考えられます ( 2.6年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
James Swift	CEO & Director	1.5yrs	US$2.24m	0.20% $ 1.7m
Mark Ordan	Chair	4.2yrs	US$554.45k	0.20% $ 1.7m
Guy Sansone	Lead Independent Director	4.2yrs	US$295.00k	0.081% $ 695.2k
Thomas McEachin	Independent Director	4.2yrs	US$252.50k	0.065% $ 556.1k
Sylvia Young	Independent Director	1.3yrs	US$201.00k	0.035% $ 297.0k
John Starcher	Independent Director	4.2yrs	US$230.00k	0.065% $ 556.0k
Shirley Weis	Independent Director	4.2yrs	US$245.00k	0.043% $ 366.6k
Gavin Molinelli	Board Observer	4.2yrs	データなし	データなし
Michael Rucker	Independent Director	5.3yrs	US$242.50k	0.069% $ 591.8k
Laura Linynsky	Independent Director	2.3yrs	US$230.00k	0.023% $ 197.9k

4.2yrs

平均在職期間

61yo

平均年齢

経験豊富なボード: PDCの取締役会は経験豊富であると考えられます ( 4.1年の平均在任期間)。

Pediatrix Medical Group マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Executive VP & CFO recently sold €461k worth of stock

Pediatrix Medical Group, Inc., Annual General Meeting, May 09, 2024

CEO & Director recently sold €172k worth of stock

Independent Director recently sold €238k worth of stock

Pediatrix Medical Group, Inc. Appoints Sylvia Young as an Independent Director, Effective May 12, 2023

Pediatrix Medical Group, Inc. Announces Executive Changes

Recent updates

Executive VP & CFO recently sold €461k worth of stock

New minor risk - Shareholder dilution

New minor risk - Share price stability

Pediatrix Medical Group, Inc. to Report Q2, 2024 Results on Aug 06, 2024

First quarter 2024 earnings released: EPS: US$0.048 (vs US$0.17 in 1Q 2023)

Pediatrix Medical Group, Inc. to Report Q1, 2024 Results on May 07, 2024

Pediatrix Medical Group, Inc., Annual General Meeting, May 09, 2024

Full year 2023 earnings released: US$0.73 loss per share (vs US$0.75 profit in FY 2022)

Pediatrix Medical Group, Inc. to Report Q4, 2023 Results on Feb 20, 2024

Investor sentiment deteriorates as stock falls 17%

New major risk - Revenue and earnings growth

Third quarter 2023 earnings released: EPS: US$0.26 (vs US$0.35 in 3Q 2022)

Pediatrix Medical Group, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Second quarter 2023 earnings released: EPS: US$0.34 (vs US$0.36 in 2Q 2022)

CEO & Director recently sold €172k worth of stock

Independent Director recently sold €238k worth of stock

Pediatrix Medical Group, Inc. Appoints Sylvia Young as an Independent Director, Effective May 12, 2023

First quarter 2023 earnings released: EPS: US$0.17 (vs US$0.24 loss in 1Q 2022)

Full year 2022 earnings released: EPS: US$750 (vs US$1.27 in FY 2021)

Pediatrix Medical Group, Inc. Announces Executive Changes

CEO & Director recently sold €334k worth of stock

High number of new and inexperienced directors

Executive VP & Chief Operating Officer recently sold €368k worth of stock

Third quarter 2022 earnings released: EPS: US$0.35 (vs US$0.37 in 3Q 2021)

Pediatrix Medical Group, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Pediatrix Medical Group, Inc. Announces Executive Changes

Second quarter 2022 earnings released: EPS: US$0.36 (vs US$0.36 in 2Q 2021)

Pediatrix Medical Group, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Mednax Announces Leadership Appointments

First quarter 2022 earnings released: US$0.24 loss per share (vs US$0.063 profit in 1Q 2021)

High number of new directors

MEDNAX, Inc. to Report Q1, 2022 Results on Apr 28, 2022

MEDNAX, Inc., Annual General Meeting, May 12, 2022

MEDNAX, Inc. Announces Resignation of Roger Mack Hinson as President of Pediatrix and Obstetrix Medical Group, Effective as of June 1, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

MEDNAX, Inc. Provides Earnings Guidance for the Year 2022

MEDNAX, Inc. to Report Q4, 2021 Results on Feb 17, 2022

MEDNAX, Inc. (NYSE:MD) acquired Night Lite Pediatrics.

Senior VP & Chief Accounting Officer recently sold €215k worth of stock

Third quarter 2021 earnings released: EPS US$0.37 (vs US$0.032 loss in 3Q 2020)

Senior VP & Chief Accounting Officer recently sold €268k worth of stock

Second quarter 2021 earnings released: EPS US$0.36 (vs US$0.085 in 2Q 2020)

New 90-day high: €23.60

Full year 2020 earnings released: US$0.12 loss per share (vs US$13.77 loss in FY 2019)

Revenue misses expectations

MEDNAX, Inc. to Report Q4, 2020 Results on Feb 18, 2021

New 90-day high: €20.00

Federman & Sherwood Files First Data Breach Case Against MedNax, Inc. and Pediatrix Medical Group

New 90-day high: €19.60

New 90-day high: €17.20

New 90-day high: €16.60

Revenue misses expectations

Third quarter 2020 earnings released: US$0.032 loss per share

New 90-day low: €12.80

New 90-day low: €14.10

Executive VP recently sold €352k worth of stock

New 90-day high - €17.30

MEDNAX, Inc. to Report Q2, 2020 Results on Jul 30, 2020

MEDNAX, Inc. Announces Executive Change

MEDNAX, Inc.(NYSE:MD) dropped from Russell 1000 Dynamic Index

MEDNAX, Inc.(NYSE:MD) dropped from Russell 1000 Index

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

マネジメント基準チェック /24